Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols

作者:Burkhardt B*; Oschlies I; Klapper W; Zimmermann M; Woessmann W; Meinhardt A; Landmann E; Attarbaschi A; Niggli F; Schrappe M; Reiter A
来源:Leukemia, 2011, 25(1): 153-160.
DOI:10.1038/leu.2010.245

摘要

Age-related differences in the distribution, biology and treatment response of non-Hodgkin's lymphoma (NHL) in adolescents remain to be elucidated. The current analyses present clinical parameters and outcomes of adolescents treated in pediatric NHL-BFM trials. Patients were stratified by histological subtype: lymphoblastic lymphoma (LBL); mature B-NHL, including Burkitt's lymphoma/leukemia (BL/B-AL), diffuse B-cell lymphoma (DLBCL-CB) and mediastinal B-cell lymphoma (PMLBL); and anaplastic large cell lymphoma (ALCL). Between October 1986 and December 2007, 2915 patients were registered, including 378 (13%) adolescents (15-18 years) with BL/B-AL (n = 101), ALCL (n = 74), DLBCL-CB (n = 55), T-LBL (n = 45), PMLBL (n = 24), pB-LBL (n = 13) and rare or not-specified NHL subtypes (n = 66). The 5-year event-free survival (EFS) was 79 +/- 2% for adolescents compared with 85 +/- 1% for patients aged <15 years (P = 0.014). EFS was 83 +/- 7% for adolescents with T-LBL, 82 +/- 4% with BL/B-AL, 85 +/- 5% with DLBCL-CB, 57 +/- 10% with PMLBL and 70 +/- 6% with ALCL. According to sex, the 5-year EFS in females versus males, respectively, was 70 +/- 5 versus 83 +/- 2% overall (P = 0.004), 57 +/- 17 versus 92 +/- 6% (P = 0.0036) for T-LBL patients and 71 +/- 9 versus 97 +/- 3% (P = 0.0067) for DLBCL-CB patients. Adolescents with NHL treated according to pediatric NHL-BFM protocols had an EFS of 79 +/- 2%, which is marginally inferior to that of children. In adolescents with T-LBL and DLBCL-CB, female sex was associated with a worse prognosis. Leukemia (2011) 25, 153-160; doi: 10.1038/leu.2010.245; published online 29 October 2010

  • 出版日期2011-1